ClinicalTrials.gg
CompletedNCT03983980Updated Jun 12, 2025Results posted

Tapinarof for the Treatment of Plaque Psoriasis in Adults (3002)

A Phase 3 interventional study of Tapinarof and Vehicle Cream in Plaque Psoriasis, sponsored by Organon and Co. Completed at 50 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-06-12.

Sponsored by Organon and Co · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
515
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing tapinarof in Psoriasis — 3 open to participants now, 3 under way, 1 of them phase 3. tapinarof · Psoriasis.

Enrollment
4th of 19
515 · median 58
Started
2019
with 3 others
Phase 3
5 of 19
none open now
Registered
7th of 19
by date
Lead sponsor
7 of 19
Organon and Co

Among the 19 studies testing tapinarof in Psoriasis, this one is the 4th largest by enrollment, is one of 4 that started in 2019, is one of 5 in phase 3, and was the 7th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

3 of the 19 studies testing tapinarof in Psoriasis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About tapinarof

tapinarof: first FDA approval 2022 (VTAMA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing tapinarof in Psoriasis, or all of them as a file.
02

Study summary

This is a randomized double-blind vehicle-controlled Phase 3 study to evaluate the efficacy and safety of topical tapinarof cream, 1% once daily for the treatment of plaque psoriasis in adults. Approximately 500 adult subjects with plaque psoriasis will be randomized 2:1 to receive either tapinarof cream, 1% or matching vehicle cream once daily for 12 weeks.

Read the detailed description

This study is a 12-week double-blind, vehicle-controlled treatment study in which subjects will be randomized to receive tapinarof cream, 1% or vehicle cream once daily for 12 weeks. At the end of the 12-week study treatment, qualified subjects completing the study will have the option to enter a separate open-label, long-term safety and efficacy study for an additional 40 weeks of treatment with tapinarof cream, 1%. Subjects who do not enroll in the open-label long-term study will complete a follow-up visit approximately 4 weeks after end of treatment in this study (at Week 16).

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

Keywords

  • Tapinarof
  • plaque psoriasis
  • adult
  • phase 3
  • topical
  • double-blind
  • efficacy
  • safety
  • psoriasis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects ages 18 to 75 years with clinical diagnosis of chronic plaque psoriasis and stable disease for at least 6 months prior to the study.
  • BSA involvement ≥ 3% and ≤ 20%
  • A PGA score of 2 (mild), 3 (moderate) or 4 (severe) at screening and baseline
  • Females of child bearing potential and male subjects who are engaging in sexual activity that could lead to pregnancy agree to follow the specified guidance throughout the study, including screening, during the treatment period, and for at least 4 weeks after the last exposure to study treatment
  • Capable of giving written

Exclusion criteria

Exclusion Criteria:

  • Psoriasis other than plaque variant
  • Any sign of infection of any of the psoriatic lesions
  • Concurrent conditions or history of other diseases:
  • at Screening
  • Chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 4 weeks prior to the Baseline visit
  • Acute active bacterial, fungal, or viral (herpes simplex, herpes zoster, chicken pox) skin infection within 1 week prior to the Baseline visit
  • Significant dermatologic or inflammatory condition other than plaque psoriasis that, in the Investigator's opinion, would make it difficult to interpret data or assessments during the study
  • (ALT) or aspartate aminotransferase (AST) ≥ 1.5x the (ULN)
  • Total > 1.5 x ULN; total bilirubin > ULN and ≤ 1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin \< 35%
  • interval > 475
  • Current or chronic history of liver disease, known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones), presence of surface antigen (HBsAg), or positive antibody test result, or a positive anti-hepatitis B core antigen (anti-HBc) result
  • Ultraviolet (UV) light therapy or prolonged exposure to natural or artificial sources of UV radiation within 4 weeks prior to the Baseline visit and/or plans to have such exposures during the study which could potentially impact the subject's psoriasis
  • Use of any prohibited medication within the indicated period before the first dose of study drug
  • Within a minimum of 5 half-lives for biologic agents:

    • Within 4 weeks for systemic immunosuppressive or immunomodulating agents, fumaric acid derivatives, vitamin D3 and analogs, retinoids, psolarens, , adrenocorticotropic hormone analogs, and tazarotene
    • 2 weeks for immunizations with a live viral component; drugs known to possibly worsen psoriasis, unless on a stable dose for > 12 weeks
    • With the exception of non-medicated emollients, 2 weeks for topical treatments including corticosteroids, immunomodulators, anthralin (dithranol), vitamin D derivatives or coal tar.
  • Pregnant females or lactating females
  • History of sensitivity to the study drugs, or components thereof or a history of drug or other allergy that, in the opinion of the Investigator or Medical Monitor, contraindicates the subject's participation in the study
  • The subject has received an product within 30 days, 5 half-lives, or twice the duration of the biological effect of the study drug (whichever is longer) prior to first dose of study drug
  • Current or a history of cancer within 5 years except for fully excised skin basal cell carcinoma, squamous cell carcinoma or carcinoma in situ of the cervix
  • Subjects with active infection that required oral, intramuscular, or intravenous administration of antibiotics, antifungal or antiviral agents within 7 days of Baseline/Day 1
  • Previous known participation in a clinical study with tapinarof
  • Evidence of significant hepatic, renal, respiratory, endocrine, hematologic, neurologic, psychiatric, or CV system abnormalities or laboratory abnormality that will affect the health of the subject or interfere with interpretation of the results
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
515 participants (actual)

Study arms

  • Experimental
    Tapinarof (DMVT-505) Cream Group

    Tapinarof cream, 1%, applied once daily

    Drug: Tapinarof

  • Placebo comparator
    Vehicle Cream Group

    Vehicle cream applied once daily

    Drug: Vehicle Cream

Interventions

  • Tapinarof cream, 1%, applied once daily

    Also known as: DMVT-505

  • DrugVehicle Cream

    Vehicle cream applied once daily

06

What researchers measure

Primary outcomes

  1. Percent of Subjects Who Achieve a Physician Global Assessment (PGA) Score of Clear (0) or Almost Clear (1) With a Minimum 2-grade Improvement From Baseline at Week 12. Analyses Were Done Using Multiple Imputation

    The PGA is a clinical tool for assessing the current state/severity of a subject's psoriasis at a given timepoint. A static 5-point scale is used to grade lesions on the clinical characteristics of erythema, scaling, and plaque thickness/elevation. The PGA ranges from 0 to 4, and is calculated as Clear (0), Almost clear (1), Mild (2), Moderate (3), and Severe (4). Higher PGA scores represent more severe disease. Analyses were done using multiple imputation

    Time frame: Baseline to Week 12

Secondary outcomes

  1. Percent of Subjects With ≥ 75% Improvement in Psoriasis Area and Severity Index (PASI) From Baseline at Week 12. Analyses Were Done Using Multiple Imputation.

    The Psoriasis Area and Severity Index (PASI) scoring system combines the assessment of lesion severity and extent of affected area into a single score: 0 (no disease) to 72 (maximal disease). The body is divided into 4 areas for scoring (head, arms, trunk, and legs). Each area is assessed for 3 signs: erythema (redness), induration (plaque thickness), and scale. The severity of each sign in each body area is assessed and scored independently using a 5-point scale, where 0=none, 1=slight, 2=mild, 3=moderate, 4=severe. Each area is also assessed for percent of skin involved: 0 = (0%), 1 = (1-\<10%), 2 = (10-\<30%), 3 = (30-\<50%), 4 = (50 -\<70%), 5 = (70-\<90%), 6 = (90-100%). The individual scores are multiplied by a weighted factor for each body region; the sum of these scores gives the overall PASI score. Higher scores indicate more severe disease. PASI is a static assessment made without reference to previous scores. Analyses were done using multiple imputation.

    Time frame: Baseline to Week 12

  2. Percent of Subjects With a PGA Score of 0 or 1 at Week 12. Analyses Were Done Using Multiple Imputation.

    The PGA is a clinical tool for assessing the current state/severity of a subject's psoriasis at a given timepoint. A static 5-point scale is used to grade lesions on the clinical characteristics of erythema, scaling, and plaque thickness/elevation. The PGA ranges from 0 to 4, and is calculated as Clear (0), Almost clear (1), Mild (2), Moderate (3), and Severe (4). Higher PGA scores represent more severe disease. Analyses were done using multiple imputation.

    Time frame: Baseline to Week 12

  3. Mean Change in Percent of Total Body Surface Area (%BSA) Affected From Baseline to Week 12

    Assessment of BSA with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. Body regions are assigned specific number of handprints with percentage \[Head and neck = 10% (10 handprints), upper extremities = 20% (20 handprints), Trunk (including axillae and groin) = 30% (30 handprints), lower extremities (including buttocks) = 40% (40 handprints)\]. Estimates of the % involvement in each body region will be multiplied by the fraction of total body area to obtain the total %BSA involved by region and overall.

    Time frame: Baseline to Week 12

  4. Percent of Subjects With ≥90% Improvement in PASI Score From Baseline to Week 12. Analyses Were Done Using Multiple Imputation.

    The Psoriasis Area and Severity Index (PASI) scoring system combines the assessment of lesion severity and extent of affected area into a single score: 0 (no disease) to 72 (maximal disease). The body is divided into 4 areas for scoring (head, arms, trunk, and legs). Each area is assessed for 3 signs: erythema (redness), induration (plaque thickness), and scale. The severity of each sign in each body area is assessed and scored independently using a 5-point scale, where 0=none, 1=slight, 2=mild, 3=moderate, 4=severe. Each area is also assessed for percent of skin involved: 0 = (0%), 1 = (1-\<10%), 2 = (10-\<30%), 3 = (30-\<50%), 4 = (50 -\<70%), 5 = (70-\<90%), 6 = (90-100%). The individual scores are multiplied by a weighted factor for each body region; the sum of these scores gives the overall PASI score. Higher scores indicate more severe disease. PASI is a static assessment made without reference to previous scores. Analyses were done using multiple imputation.

    Time frame: Baseline to Week 12

07

Results

Posted Oct 13, 2022

Participant flow

Participant flow — Overall Study
MilestoneTapinarof (DMVT-505) Cream GroupVehicle Cream Group
Started343172
Completed282142
Not completed6130

Outcome measures

PrimaryPercent of Subjects Who Achieve a Physician Global Assessment (PGA) Score of Clear (0) or Almost Clear (1) With a Minimum 2-grade Improvement From Baseline at Week 12. Analyses Were Done Using Multiple Imputation

The PGA is a clinical tool for assessing the current state/severity of a subject's psoriasis at a given timepoint. A static 5-point scale is used to grade lesions on the clinical characteristics of erythema, scaling, and plaque thickness/elevation. The PGA ranges from 0 to 4, and is calculated as Clear (0), Almost clear (1), Mild (2), Moderate (3), and Severe (4). Higher PGA scores represent more severe disease. Analyses were done using multiple imputation

Time frame:
Baseline to Week 12
Reported as:
Mean · percentage of subjects
Percent of Subjects Who Achieve a Physician Global Assessment (PGA) Score of Clear (0) or Almost Clear (1) With a Minimum 2-grade Improvement From Baseline at Week 12. Analyses Were Done Using Multiple Imputation
percentage of subjectsTapinarof (DMVT-505) Cream GroupVehicle Cream Group
Percent of Subjects Who Achieve a Physician Global Assessment (PGA) Score of Clear (0) or Almost Clear (1) With a Minimum 2-grade Improvement From Baseline at Week 12. Analyses Were Done Using Multiple Imputation40.2 ± 2.826.3 ± 1.99
Statistical analysis
  • Tapinarof (DMVT-505) Cream Group vs Vehicle Cream Group · Cochran-Mantel-Haenszel · p = <0.0001 · Risk ratio (rr): 6.10
SecondaryPercent of Subjects With ≥ 75% Improvement in Psoriasis Area and Severity Index (PASI) From Baseline at Week 12. Analyses Were Done Using Multiple Imputation.

The Psoriasis Area and Severity Index (PASI) scoring system combines the assessment of lesion severity and extent of affected area into a single score: 0 (no disease) to 72 (maximal disease). The body is divided into 4 areas for scoring (head, arms, trunk, and legs). Each area is assessed for 3 signs: erythema (redness), induration (plaque thickness), and scale. The severity of each sign in each body area is assessed and scored independently using a 5-point scale, where 0=none, 1=slight, 2=mild, 3=moderate, 4=severe. Each area is also assessed for percent of skin involved: 0 = (0%), 1 = (1-\<10%), 2 = (10-\<30%), 3 = (30-\<50%), 4 = (50 -\<70%), 5 = (70-\<90%), 6 = (90-100%). The individual scores are multiplied by a weighted factor for each body region; the sum of these scores gives the overall PASI score. Higher scores indicate more severe disease. PASI is a static assessment made without reference to previous scores. Analyses were done using multiple imputation.

Time frame:
Baseline to Week 12
Reported as:
Mean · percentage of subjects
Percent of Subjects With ≥ 75% Improvement in Psoriasis Area and Severity Index (PASI) From Baseline at Week 12. Analyses Were Done Using Multiple Imputation.
percentage of subjectsTapinarof (DMVT-505) Cream GroupVehicle Cream Group
Percent of Subjects With ≥ 75% Improvement in Psoriasis Area and Severity Index (PASI) From Baseline at Week 12. Analyses Were Done Using Multiple Imputation.47.6 ± 2.816.9 ± 2.01
Statistical analysis
  • Tapinarof (DMVT-505) Cream Group vs Vehicle Cream Group · Cochran-Mantel-Haenszel · p = <0.0001 · Risk ratio (rr): 6.53
SecondaryPercent of Subjects With a PGA Score of 0 or 1 at Week 12. Analyses Were Done Using Multiple Imputation.

The PGA is a clinical tool for assessing the current state/severity of a subject's psoriasis at a given timepoint. A static 5-point scale is used to grade lesions on the clinical characteristics of erythema, scaling, and plaque thickness/elevation. The PGA ranges from 0 to 4, and is calculated as Clear (0), Almost clear (1), Mild (2), Moderate (3), and Severe (4). Higher PGA scores represent more severe disease. Analyses were done using multiple imputation.

Time frame:
Baseline to Week 12
Reported as:
Mean · percentage of subjects
Percent of Subjects With a PGA Score of 0 or 1 at Week 12. Analyses Were Done Using Multiple Imputation.
percentage of subjectsTapinarof (DMVT-505) Cream GroupVehicle Cream Group
Percent of Subjects With a PGA Score of 0 or 1 at Week 12. Analyses Were Done Using Multiple Imputation.43.6 ± 2.858.1 ± 2.21
Statistical analysis
  • Tapinarof (DMVT-505) Cream Group vs Vehicle Cream Group · Cochran-Mantel-Haenszel · p = <0.0001 · Risk ratio (rr): 4.55
SecondaryMean Change in Percent of Total Body Surface Area (%BSA) Affected From Baseline to Week 12

Assessment of BSA with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. Body regions are assigned specific number of handprints with percentage \[Head and neck = 10% (10 handprints), upper extremities = 20% (20 handprints), Trunk (including axillae and groin) = 30% (30 handprints), lower extremities (including buttocks) = 40% (40 handprints)\]. Estimates of the % involvement in each body region will be multiplied by the fraction of total body area to obtain the total %BSA involved by region and overall.

Time frame:
Baseline to Week 12
Reported as:
Mean · Mean change from Baseline
Mean Change in Percent of Total Body Surface Area (%BSA) Affected From Baseline to Week 12
Mean change from BaselineTapinarof (DMVT-505) Cream GroupVehicle Cream Group
Mean Change in Percent of Total Body Surface Area (%BSA) Affected From Baseline to Week 12-4.22 ± 0.3670.10 ± 0.448
Statistical analysis
  • Tapinarof (DMVT-505) Cream Group vs Vehicle Cream Group · ANCOVA · p = <0.0001 · Least squares mean difference: -4.32
SecondaryPercent of Subjects With ≥90% Improvement in PASI Score From Baseline to Week 12. Analyses Were Done Using Multiple Imputation.

The Psoriasis Area and Severity Index (PASI) scoring system combines the assessment of lesion severity and extent of affected area into a single score: 0 (no disease) to 72 (maximal disease). The body is divided into 4 areas for scoring (head, arms, trunk, and legs). Each area is assessed for 3 signs: erythema (redness), induration (plaque thickness), and scale. The severity of each sign in each body area is assessed and scored independently using a 5-point scale, where 0=none, 1=slight, 2=mild, 3=moderate, 4=severe. Each area is also assessed for percent of skin involved: 0 = (0%), 1 = (1-\<10%), 2 = (10-\<30%), 3 = (30-\<50%), 4 = (50 -\<70%), 5 = (70-\<90%), 6 = (90-100%). The individual scores are multiplied by a weighted factor for each body region; the sum of these scores gives the overall PASI score. Higher scores indicate more severe disease. PASI is a static assessment made without reference to previous scores. Analyses were done using multiple imputation.

Time frame:
Baseline to Week 12
Reported as:
Mean · percentage of subjects
Percent of Subjects With ≥90% Improvement in PASI Score From Baseline to Week 12. Analyses Were Done Using Multiple Imputation.
percentage of subjectsTapinarof (DMVT-505) Cream GroupVehicle Cream Group
Percent of Subjects With ≥90% Improvement in PASI Score From Baseline to Week 12. Analyses Were Done Using Multiple Imputation.20.9 ± 2.282.5 ± 1.21
Statistical analysis
  • Tapinarof (DMVT-505) Cream Group vs Vehicle Cream Group · Cochran-Mantel-Haenszel · p = <0.0001 · Risk ratio (rr): 7.25

Adverse events

Collected over Subject duration: 12 weeks of treatment and 4 week follow-up for subjects not enrolled in the long-term extension study (DMVT-505-3003). Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tapinarof (DMVT-505) Cream Group0/343 (0%)7/343 (2%)123/343 (35.9%)
Vehicle Cream Group0/172 (0%)0/172 (0%)28/172 (16.3%)
Most frequent serious events
Most frequent serious events
EventTapinarof (DMVT-505) Cream GroupVehicle Cream Group
Coronary artery stenosisCardiac disorders1/3430/172
PancreatitisGastrointestinal disorders1/3430/172
CholelithiasisHepatobiliary disorders1/3430/172
AppendicitisInfections and infestations1/3430/172
HeadacheNervous system disorders1/3430/172
Nerve compressionNervous system disorders1/3430/172
NephrolithiasisRenal and urinary disorders1/3430/172
Most frequent other events
Showing 10 of 16
Most frequent other events
EventTapinarof (DMVT-505) Cream GroupVehicle Cream Group
FolliculitisInfections and infestations59/3431/172
Dermatitis contactSkin and subcutaneous tissue disorders18/3430/172
Upper respiratory tract infectionInfections and infestations12/3438/172
NasopharyngitisInfections and infestations14/3435/172
HeadacheNervous system disorders13/3431/172
PruritusSkin and subcutaneous tissue disorders7/3432/172
BronchitisInfections and infestations6/3431/172
SinusitisInfections and infestations6/3431/172
Back painMusculoskeletal and connective tissue disorders2/3433/172
Urinary tract infectionInfections and infestations5/3432/172

Baseline characteristics

Age, Continuous
Age, Continuous(years)Tapinarof (DMVT-505) Cream GroupVehicle Cream GroupTotal
Mean50.0 ± 13.0750.0 ± 13.6750.0 ± 13.26
Sex: Female, Male
Sex: Female, Male(Participants)Tapinarof (DMVT-505) Cream GroupVehicle Cream GroupTotal
Female15570225
Male188102290
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Tapinarof (DMVT-505) Cream GroupVehicle Cream GroupTotal
Hispanic or Latino432366
Not Hispanic or Latino300148448
Unknown or Not Reported011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Tapinarof (DMVT-505) Cream GroupVehicle Cream GroupTotal
American Indian or Alaska Native224
Asian252146
Native Hawaiian or Other Pacific Islander011
Black or African American12618
White300138438
More than one race336
Unknown or Not Reported112
Physicians Global Assessment
Physicians Global Assessment(Participants)Tapinarof (DMVT-505) Cream GroupVehicle Cream GroupTotal
0 - Clear000
1 - Almost Clear000
2 - Mild281543
3 - Moderate288144432
4 - severe271340
Psoriasis Area and Severity Index
Psoriasis Area and Severity Index(units on a scale)Tapinarof (DMVT-505) Cream GroupVehicle Cream GroupTotal
Mean9.05 ± 3.6769.27 ± 4.0169.12 ± 3.791
Percent Body Surface Area
Percent Body Surface Area(Percent)Tapinarof (DMVT-505) Cream GroupVehicle Cream GroupTotal
Mean7.8 ± 4.397.3 ± 4.147.6 ± 4.31
08

Study locations

50 sites
  • Dermavant Investigative Site
    Fort Smith, Arkansas 72916, United States
  • Dermavant Investigative Site
    Fountain Valley, California 92708, United States
  • Dermavant Investigative Site
    Fremont, California 94538, United States
  • Dermavant Investigative Site
    Los Angeles, California 90045, United States
  • Dermavant Investigative Site
    Oceanside, California 92056, United States
  • Dermavant Investigative Site
    San Diego, California 92123, United States
  • Dermavant Investigative Site
    Santa Monica, California 90404, United States
  • Dermavant Investigative Site
    Denver, Colorado 80210, United States
  • Dermavant Investigative Site
    Boynton Beach, Florida 33437, United States
  • Dermavant Investigative Site
    Margate, Florida 33414, United States
  • Dermavant Investigative Site
    Miami, Florida 33144, United States
  • Dermavant Investigative Site
    Boise, Idaho 83713, United States
  • Dermavant Investigative Site
    Rolling Meadows, Illinois 60008, United States
  • Dermavant Investigative Site
    Plainfield, Indiana 46168, United States
  • Dermavant Investigative Site
    Overland Park, Kansas 66215, United States
  • Dermavant Investigative Site
    Louisville, Kentucky 40217, United States
  • Dermavant Investigative Site
    Owensboro, Kentucky 42301, United States
  • Dermavant Investigative Site
    Metairie, Louisiana 70006, United States
  • Dermavant Investigative Site
    Boston, Massachusetts 02215, United States
  • Dermavant Investigative Site
    Bay City, Michigan 48706, United States
  • Dermavant Investigative Site
    Detroit, Michigan 48202, United States
  • Dermavant Investigative Site
    Fort Gratiot, Michigan 48059, United States
  • Dermavant Investigative Site
    Fridley, Minnesota 55432, United States
  • Dermavant Investigative Site
    Omaha, Nebraska 68144, United States
  • Dermavant Investigative Site
    Las Vegas, Nevada 89148, United States
  • Dermavant Investigative Site
    East Windsor, New Jersey 08520, United States
  • Dermavant Investigative Site
    Hackensack, New Jersey 07601, United States
  • Dermavant Investigative Site
    Stony Brook, New York 11790, United States
  • Dermavant Investigative Site
    Wilmington, North Carolina 28405, United States
  • Dermavant Investigative Site
    Winston-Salem, North Carolina 27157, United States
  • Dermavant Investigative Site
    Beachwood, Ohio 44122, United States
  • Dermavant Investigative Site
    Bexley, Ohio 43209, United States
  • Dermavant Investigative Site
    Portland, Oregon 97223, United States
  • Dermavant Investigative Site
    Charleston, South Carolina 29414, United States
  • Dermavant Investigative Site
    Nashville, Tennessee 37215, United States
  • Dermavant Investigative Site
    Houston, Texas 77056, United States
  • Dermavant Investigative Site
    Pflugerville, Texas 78660, United States
  • Dermavant Investigative Site
    Plano, Texas 75024, United States
  • Dermavant Investigative Site
    San Antonio, Texas 78229, United States
  • Dermavant Investigative Site
    Webster, Texas 77598, United States
  • Dermavant Investigative Site
    Norfolk, Virginia 23502, United States
  • Dermavant Investigative Site
    Spokane, Washington 99202, United States
  • Dermavant Investigative Site
    Edmonton, Alberta T5K 1X3, Canada
  • Dermavant Investigative Site
    Surrey, Bristish Columbia V3R 6A7, Canada
  • Dermavant Investigative Site
    Surrey, Bristish Columbia V3V 0C6, Canada
  • Dermavant Investigative Site
    Etobicoke, Ontario M9A 3P2, Canada
  • Dermavant Investigative Site
    Hamilton, Ontario L8N 1Y2, Canada
  • Dermavant Investigative Site
    Markham, Ontario L3P 1X2, Canada
  • Dermavant Investigative Site
    Oakville, Ontario L6J 7W5, Canada
  • Dermavant Investigative Site
    Ottawa, Ontario K2C 3N2, Canada
09

References and documents

Publications

  • Lebwohl MG, Stein Gold L, Strober B, Papp KA, Armstrong AW, Bagel J, Kircik L, Ehst B, Hong HC, Soung J, Fromowitz J, Guenthner S, Piscitelli SC, Rubenstein DS, Brown PM, Tallman AM, Bissonnette R. Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis. N Engl J Med. 2021 Dec 9;385(24):2219-2229. doi: 10.1056/NEJMoa2103629. PubMed 34879448 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2019 to primary completion in May 2020, 11 months.

Results were first posted in Oct 2022, 2 years 5 months after primary completion. A results delay was requested in Oct 2020.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 11 months is below that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2019
First posted
Jun 12, 2019
StartActual
Jun 6, 2019
Primary completionActual
May 13, 2020
CompletionActual
May 29, 2020
Results delay requested
Oct 7, 2020
Results first posted
Oct 13, 2022
Last update
Jun 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03983980
Lead sponsor
Organon and Co
Collaborators
IQVIA Biotech
Responsible party
Sponsor
First posted
Jun 12, 2019
Start date
Jun 6, 2019
Primary completion
May 13, 2020
Completion
May 29, 2020
Results posted
Oct 13, 2022
Last update
Jun 12, 2025

Study contacts

Victoria Butners
study director · Dermavant Sciences GmbH

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tapinarof

Start the discussion